Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RadProtect
- Development stage
- Phase 1
- Lead developer
- Original BioMedicals
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous (based On Typical Use Of Amifostine Derivatives; Specific Route For This Formulation Not Explicitly Stated But Likely Similar)
01
Overview
RadProtect is an investigational radioprotective drug designed to prevent or reduce radiation injury when administered prior to exposure. It is a novel formulation based on the FDA-approved drug amifostine, modified by Original BioMedicals to improve its properties for radiation protection. The formulation uses ferrous iron as a linkage between PEG-b-PGA (polyethylene glycol-block-polyglutamic acid) and amifostine, but it is not a fully closed micelle system. This design aims to enhance the pharmacokinetics and safety profile of amifostine, potentially allowing higher tolerated doses and improved efficacy in protecting healthy tissues from radiation damage during cancer therapy or accidental exposure[2][3][4]. The primary mechanism of action involves scavenging free radicals generated by ionizing radiation, thereby reducing DNA damage in normal cells.
- Brand names
- RadProtect
- Other names
- RadProtect
02
Targets
ROS/RNS (Ionizing radiation-induced free radicals)
Beyond the preview
Go deeper on RadProtect.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RadProtect.